STOCK TITAN

[8-K] Inovio Pharmaceuticals, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

HSBC Holdings plc (HSBC) filed a Form 6-K detailing progress on the US$3bn share-buyback programme announced on 6 May 2025. On 4 July 2025 the bank repurchased a combined 601,094 ordinary shares (par value US$0.50) across UK and Hong Kong trading venues:

  • UK Venues: 267,494 shares at a volume-weighted average price (VWAP) of £8.8395 (high £8.8670; low £8.8030).
  • Hong Kong Stock Exchange: 333,600 shares at a VWAP of HK$94.7092 (high HK$94.85; low HK$94.50).

Since programme launch, 199,313,865 shares have been acquired for an aggregate consideration of ≈US$2.33 billion.

The company also cancelled 20,746,000 shares previously repurchased in Hong Kong. After these cancellations, outstanding issued share capital stands at 17,456,148,272 ordinary shares carrying voting rights; no shares are held in treasury. HSBC will publish a further total-voting-rights notice once remaining Hong Kong repurchases are cancelled.

The buyback—executed by Morgan Stanley—continues to be treated as market purchases under UK Companies Act 2006 and as on-market transactions under Hong Kong listing rules. Full trade details are available via the linked RNS PDF.

HSBC Holdings plc (HSBC) ha presentato un modulo 6-K che illustra i progressi del programma di riacquisto di azioni da 3 miliardi di dollari USA annunciato il 6 maggio 2025. Il 4 luglio 2025 la banca ha riacquistato complessivamente 601.094 azioni ordinarie (valore nominale US$0,50) sui mercati del Regno Unito e di Hong Kong:

  • Mercati del Regno Unito: 267.494 azioni a un prezzo medio ponderato per il volume (VWAP) di £8,8395 (massimo £8,8670; minimo £8,8030).
  • Borsa di Hong Kong: 333.600 azioni a un VWAP di HK$94,7092 (massimo HK$94,85; minimo HK$94,50).

Dal lancio del programma, sono state acquistate 199.313.865 azioni per un valore complessivo di circa 2,33 miliardi di dollari USA.

L’azienda ha inoltre annullato 20.746.000 azioni precedentemente riacquistate a Hong Kong. Dopo queste cancellazioni, il capitale sociale emesso in circolazione ammonta a 17.456.148.272 azioni ordinarie con diritto di voto; non sono detenute azioni in tesoreria. HSBC pubblicherà un ulteriore avviso relativo ai diritti di voto totali una volta completate le cancellazioni delle azioni riacquistate a Hong Kong.

Il riacquisto, eseguito da Morgan Stanley, continua a essere trattato come acquisti di mercato secondo il Companies Act 2006 del Regno Unito e come transazioni sul mercato secondo le regole di quotazione di Hong Kong. I dettagli completi delle operazioni sono disponibili nel PDF RNS collegato.

HSBC Holdings plc (HSBC) presentó un Formulario 6-K detallando el progreso del programa de recompra de acciones por US$3 mil millones anunciado el 6 de mayo de 2025. El 4 de julio de 2025 el banco recompró un total combinado de 601,094 acciones ordinarias (valor nominal US$0.50) en los mercados del Reino Unido y Hong Kong:

  • Mercados del Reino Unido: 267,494 acciones a un precio promedio ponderado por volumen (VWAP) de £8.8395 (máximo £8.8670; mínimo £8.8030).
  • Bolsa de Hong Kong: 333,600 acciones a un VWAP de HK$94.7092 (máximo HK$94.85; mínimo HK$94.50).

Desde el lanzamiento del programa, se han adquirido 199,313,865 acciones por un valor total aproximado de ≈US$2.33 mil millones.

La compañía también canceló 20,746,000 acciones previamente recompradas en Hong Kong. Tras estas cancelaciones, el capital social emitido en circulación es de 17,456,148,272 acciones ordinarias con derecho a voto; no hay acciones en tesorería. HSBC publicará otro aviso sobre el total de derechos de voto una vez que se cancelen las recompras restantes en Hong Kong.

La recompra, ejecutada por Morgan Stanley, continúa siendo tratada como compras de mercado bajo la Ley de Sociedades del Reino Unido de 2006 y como transacciones en el mercado según las normas de listado de Hong Kong. Los detalles completos de las operaciones están disponibles en el PDF RNS adjunto.

HSBC Holdings plc (HSBC)는 2025년 5월 6일에 발표한 30억 달러 규모의 자사주 매입 프로그램 진행 상황을 자세히 설명하는 Form 6-K를 제출했습니다. 2025년 7월 4일 은행은 영국 및 홍콩 거래소에서 총 601,094 보통주(액면가 미화 0.50달러)를 재매입했습니다:

  • 영국 거래소: 267,494주, 거래량 가중 평균 가격(VWAP) £8.8395 (최고 £8.8670; 최저 £8.8030).
  • 홍콩 증권거래소: 333,600주, VWAP HK$94.7092 (최고 HK$94.85; 최저 HK$94.50).

프로그램 시작 이후 199,313,865주를 약 23억 3천만 달러에 매입했습니다.

회사는 또한 홍콩에서 이전에 매입한 20,746,000주를 소각했습니다. 이 소각 이후 발행주식 총수17,456,148,272주로, 의결권이 부여된 보통주이며, 자사주는 보유하고 있지 않습니다. HSBC는 남은 홍콩 자사주 매입분이 소각되면 추가 의결권 총수 고지를 발표할 예정입니다.

이번 자사주 매입은 모건 스탠리가 실행했으며, 영국 회사법 2006에 따른 시장 매입으로, 홍콩 상장 규정에 따른 장내 거래로 처리되고 있습니다. 거래 내역 전체는 첨부된 RNS PDF에서 확인할 수 있습니다.

HSBC Holdings plc (HSBC) a déposé un formulaire 6-K détaillant les progrès du programme de rachat d'actions de 3 milliards de dollars US annoncé le 6 mai 2025. Le 4 juillet 2025, la banque a racheté un total combiné de 601 094 actions ordinaires (valeur nominale de 0,50 USD) sur les marchés du Royaume-Uni et de Hong Kong :

  • Marchés du Royaume-Uni : 267 494 actions au prix moyen pondéré par le volume (VWAP) de 8,8395 £ (plus haut 8,8670 £ ; plus bas 8,8030 £).
  • Bourse de Hong Kong : 333 600 actions au VWAP de 94,7092 HK$ (plus haut 94,85 HK$ ; plus bas 94,50 HK$).

Depuis le lancement du programme, 199 313 865 actions ont été acquises pour un montant total d’environ 2,33 milliards de dollars US.

La société a également annulé 20 746 000 actions précédemment rachetées à Hong Kong. Après ces annulations, le capital social émis en circulation s’élève à 17 456 148 272 actions ordinaires avec droit de vote ; aucune action n’est détenue en trésorerie. HSBC publiera un nouvel avis sur le total des droits de vote une fois que les rachats restants à Hong Kong seront annulés.

Le rachat — exécuté par Morgan Stanley — continue d’être traité comme des achats de marché selon le Companies Act 2006 du Royaume-Uni et comme des transactions sur le marché selon les règles de cotation de Hong Kong. Les détails complets des transactions sont disponibles dans le PDF RNS lié.

HSBC Holdings plc (HSBC) hat ein Formular 6-K eingereicht, das den Fortschritt des am 6. Mai 2025 angekündigten Aktienrückkaufprogramms über 3 Mrd. US-Dollar darlegt. Am 4. Juli 2025 hat die Bank insgesamt 601.094 Stammaktien (Nennwert 0,50 US-Dollar) an den Handelsplätzen in Großbritannien und Hongkong zurückgekauft:

  • UK-Handelsplätze: 267.494 Aktien zu einem volumen­gewichteten Durchschnittspreis (VWAP) von £8,8395 (Hoch £8,8670; Tief £8,8030).
  • Hongkonger Börse: 333.600 Aktien zu einem VWAP von HK$94,7092 (Hoch HK$94,85; Tief HK$94,50).

Seit Programmstart wurden 199.313.865 Aktien zu einem Gesamtpreis von etwa 2,33 Mrd. US-Dollar erworben.

Das Unternehmen hat zudem 20.746.000 zuvor in Hongkong zurückgekaufte Aktien storniert. Nach diesen Stornierungen beträgt das ausstehende ausgegebene Grundkapital 17.456.148.272 Stammaktien mit Stimmrechten; es werden keine eigenen Aktien gehalten. HSBC wird eine weitere Mitteilung zu den Gesamtstimmrechten veröffentlichen, sobald die verbleibenden Rückkäufe in Hongkong storniert sind.

Der Rückkauf – ausgeführt von Morgan Stanley – wird weiterhin als Marktankauf gemäß dem UK Companies Act 2006 und als On-Market-Transaktionen gemäß den Hongkonger Börsenregeln behandelt. Vollständige Handelsdetails sind im verlinkten RNS-PDF verfügbar.

Positive
  • Progress on US$3 billion buyback: 199.3 million shares already repurchased, signalling management confidence and providing EPS support.
  • Share cancellation executed: 20.7 million shares removed from register, immediately reducing share count and enhancing per-share metrics.
Negative
  • None.

Insights

TL;DR: Modest daily buyback, overall programme progressing; marginally accretive, limited immediate valuation impact.

The additional 0.6 million shares retired on 4 July represent just 0.003% of HSBC’s post-cancellation share count, so the specific day’s activity is immaterial. However, the cumulative 199.3 million shares (≈1.1% of shares outstanding pre-programme) removed since May equate to an earnings-per-share uplift of roughly the same magnitude and signal management’s confidence in capital strength (CET1 14.8% at 1Q25). At an average cost of US$11.67 per share equivalent, the spend represents c.9% of expected FY25 net profit, comfortably within the bank’s capital distribution capacity. Investors should view the update as a routine execution disclosure rather than a catalyst; nonetheless, the continuing pace suggests HSBC will complete the US$3 billion mandate on schedule, supporting total shareholder return.

HSBC Holdings plc (HSBC) ha presentato un modulo 6-K che illustra i progressi del programma di riacquisto di azioni da 3 miliardi di dollari USA annunciato il 6 maggio 2025. Il 4 luglio 2025 la banca ha riacquistato complessivamente 601.094 azioni ordinarie (valore nominale US$0,50) sui mercati del Regno Unito e di Hong Kong:

  • Mercati del Regno Unito: 267.494 azioni a un prezzo medio ponderato per il volume (VWAP) di £8,8395 (massimo £8,8670; minimo £8,8030).
  • Borsa di Hong Kong: 333.600 azioni a un VWAP di HK$94,7092 (massimo HK$94,85; minimo HK$94,50).

Dal lancio del programma, sono state acquistate 199.313.865 azioni per un valore complessivo di circa 2,33 miliardi di dollari USA.

L’azienda ha inoltre annullato 20.746.000 azioni precedentemente riacquistate a Hong Kong. Dopo queste cancellazioni, il capitale sociale emesso in circolazione ammonta a 17.456.148.272 azioni ordinarie con diritto di voto; non sono detenute azioni in tesoreria. HSBC pubblicherà un ulteriore avviso relativo ai diritti di voto totali una volta completate le cancellazioni delle azioni riacquistate a Hong Kong.

Il riacquisto, eseguito da Morgan Stanley, continua a essere trattato come acquisti di mercato secondo il Companies Act 2006 del Regno Unito e come transazioni sul mercato secondo le regole di quotazione di Hong Kong. I dettagli completi delle operazioni sono disponibili nel PDF RNS collegato.

HSBC Holdings plc (HSBC) presentó un Formulario 6-K detallando el progreso del programa de recompra de acciones por US$3 mil millones anunciado el 6 de mayo de 2025. El 4 de julio de 2025 el banco recompró un total combinado de 601,094 acciones ordinarias (valor nominal US$0.50) en los mercados del Reino Unido y Hong Kong:

  • Mercados del Reino Unido: 267,494 acciones a un precio promedio ponderado por volumen (VWAP) de £8.8395 (máximo £8.8670; mínimo £8.8030).
  • Bolsa de Hong Kong: 333,600 acciones a un VWAP de HK$94.7092 (máximo HK$94.85; mínimo HK$94.50).

Desde el lanzamiento del programa, se han adquirido 199,313,865 acciones por un valor total aproximado de ≈US$2.33 mil millones.

La compañía también canceló 20,746,000 acciones previamente recompradas en Hong Kong. Tras estas cancelaciones, el capital social emitido en circulación es de 17,456,148,272 acciones ordinarias con derecho a voto; no hay acciones en tesorería. HSBC publicará otro aviso sobre el total de derechos de voto una vez que se cancelen las recompras restantes en Hong Kong.

La recompra, ejecutada por Morgan Stanley, continúa siendo tratada como compras de mercado bajo la Ley de Sociedades del Reino Unido de 2006 y como transacciones en el mercado según las normas de listado de Hong Kong. Los detalles completos de las operaciones están disponibles en el PDF RNS adjunto.

HSBC Holdings plc (HSBC)는 2025년 5월 6일에 발표한 30억 달러 규모의 자사주 매입 프로그램 진행 상황을 자세히 설명하는 Form 6-K를 제출했습니다. 2025년 7월 4일 은행은 영국 및 홍콩 거래소에서 총 601,094 보통주(액면가 미화 0.50달러)를 재매입했습니다:

  • 영국 거래소: 267,494주, 거래량 가중 평균 가격(VWAP) £8.8395 (최고 £8.8670; 최저 £8.8030).
  • 홍콩 증권거래소: 333,600주, VWAP HK$94.7092 (최고 HK$94.85; 최저 HK$94.50).

프로그램 시작 이후 199,313,865주를 약 23억 3천만 달러에 매입했습니다.

회사는 또한 홍콩에서 이전에 매입한 20,746,000주를 소각했습니다. 이 소각 이후 발행주식 총수17,456,148,272주로, 의결권이 부여된 보통주이며, 자사주는 보유하고 있지 않습니다. HSBC는 남은 홍콩 자사주 매입분이 소각되면 추가 의결권 총수 고지를 발표할 예정입니다.

이번 자사주 매입은 모건 스탠리가 실행했으며, 영국 회사법 2006에 따른 시장 매입으로, 홍콩 상장 규정에 따른 장내 거래로 처리되고 있습니다. 거래 내역 전체는 첨부된 RNS PDF에서 확인할 수 있습니다.

HSBC Holdings plc (HSBC) a déposé un formulaire 6-K détaillant les progrès du programme de rachat d'actions de 3 milliards de dollars US annoncé le 6 mai 2025. Le 4 juillet 2025, la banque a racheté un total combiné de 601 094 actions ordinaires (valeur nominale de 0,50 USD) sur les marchés du Royaume-Uni et de Hong Kong :

  • Marchés du Royaume-Uni : 267 494 actions au prix moyen pondéré par le volume (VWAP) de 8,8395 £ (plus haut 8,8670 £ ; plus bas 8,8030 £).
  • Bourse de Hong Kong : 333 600 actions au VWAP de 94,7092 HK$ (plus haut 94,85 HK$ ; plus bas 94,50 HK$).

Depuis le lancement du programme, 199 313 865 actions ont été acquises pour un montant total d’environ 2,33 milliards de dollars US.

La société a également annulé 20 746 000 actions précédemment rachetées à Hong Kong. Après ces annulations, le capital social émis en circulation s’élève à 17 456 148 272 actions ordinaires avec droit de vote ; aucune action n’est détenue en trésorerie. HSBC publiera un nouvel avis sur le total des droits de vote une fois que les rachats restants à Hong Kong seront annulés.

Le rachat — exécuté par Morgan Stanley — continue d’être traité comme des achats de marché selon le Companies Act 2006 du Royaume-Uni et comme des transactions sur le marché selon les règles de cotation de Hong Kong. Les détails complets des transactions sont disponibles dans le PDF RNS lié.

HSBC Holdings plc (HSBC) hat ein Formular 6-K eingereicht, das den Fortschritt des am 6. Mai 2025 angekündigten Aktienrückkaufprogramms über 3 Mrd. US-Dollar darlegt. Am 4. Juli 2025 hat die Bank insgesamt 601.094 Stammaktien (Nennwert 0,50 US-Dollar) an den Handelsplätzen in Großbritannien und Hongkong zurückgekauft:

  • UK-Handelsplätze: 267.494 Aktien zu einem volumen­gewichteten Durchschnittspreis (VWAP) von £8,8395 (Hoch £8,8670; Tief £8,8030).
  • Hongkonger Börse: 333.600 Aktien zu einem VWAP von HK$94,7092 (Hoch HK$94,85; Tief HK$94,50).

Seit Programmstart wurden 199.313.865 Aktien zu einem Gesamtpreis von etwa 2,33 Mrd. US-Dollar erworben.

Das Unternehmen hat zudem 20.746.000 zuvor in Hongkong zurückgekaufte Aktien storniert. Nach diesen Stornierungen beträgt das ausstehende ausgegebene Grundkapital 17.456.148.272 Stammaktien mit Stimmrechten; es werden keine eigenen Aktien gehalten. HSBC wird eine weitere Mitteilung zu den Gesamtstimmrechten veröffentlichen, sobald die verbleibenden Rückkäufe in Hongkong storniert sind.

Der Rückkauf – ausgeführt von Morgan Stanley – wird weiterhin als Marktankauf gemäß dem UK Companies Act 2006 und als On-Market-Transaktionen gemäß den Hongkonger Börsenregeln behandelt. Vollständige Handelsdetails sind im verlinkten RNS-PDF verfügbar.

false 0001055726 0001055726 2025-07-02 2025-07-02
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 2, 2025

 

 

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-14888   33-0969592
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
 

(IRS Employer

Identification No.)

660 W. Germantown Pike, Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value   INO   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry into a Material Definitive Agreement.

On July 2, 2025, Inovio Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale by the Company in a public offering of 14,285,715 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and accompanying Series A warrants to purchase up to 14,285,715 shares of its Common Stock (or pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “Pre-Funded Warrants”) in lieu thereof) at an exercise price of $1.75 per share of common stock (or $1.749 per Pre-Funded Warrant) (the “Series A Warrants”) and Series B warrants to purchase up to 14,285,715 shares of its Common Stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.75 per share of Common Stock (or $1.749 per Pre-Funded Warrant) (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”), at a combined public offering price of $1.75 per share of Common Stock and accompanying Series A and Series B Warrants (the “Offering”).

The Company also granted the Underwriters an option for a period of 30 days to purchase up to 2,142,857 additional shares of the Company’s common stock and Series A Warrants to purchase up to 2,142,857 additional shares of its common stock and Series B Warrants to purchase up to 2,142,857 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

The net proceeds to the Company from the Offering are expected to be approximately $22.5 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, and assuming no exercise of the Underwriters’ option to purchase additional shares and the Warrants. All of the Shares and the Warrants are being sold by the Company. The closing of the Offering is expected to occur on or about July 7, 2025, subject to the satisfaction of customary closing conditions.

The Offering was made pursuant to the Company’s registration statement on Form S-3 (File No. 333-275445), which was declared effective by the Securities and Exchange Commission (the “SEC”) on January 31, 2024, as supplemented by a prospectus supplement filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).

Each Series A Warrant entitles the holder thereof to purchase one share of Common Stock at an exercise price equal to $1.75 per share (or $1.749 per Pre-Funded Warrant), will be immediately exercisable and will expire on the date that is the earlier of (i) 12 months from the date of issuance or (ii) 30 days after the date on which the Company first publicly discloses, whether by press release or Form 8-K filing, the U.S. Food and Drug Administration’s acceptance of a Biologic License Application for INO-3107. Each Series B Warrant entitles the holder thereof to purchase one share of Common Stock at an exercise price equal to $1.75 per share (or $1.749 per Pre-Funded Warrant), will be immediately exercisable and will expire five years from the date of issuance. A holder of the Warrants will not be entitled to exercise any portion of such Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates, any other persons acting as a group together with the holder and any other persons whose beneficial ownership of Common Stock would be aggregated with the holder for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended) to exceed 4.99% (or, upon election by the holder prior to the issuance of the Warrant, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise. If a holder holds less than 20% of the number of shares of Common Stock outstanding prior to giving effect to the issuance of shares issuable upon exercise, then, upon at least 61 days’ prior notice from such holder, subject to the terms of the Warrants, such holder may increase or decrease such percentage to any other percentage not in excess of 19.99%. If the holder is not permitted to exercise a Series A Warrant or a Series B Warrant for common stock due to the foregoing limitation, then the holder may exercise such Warrant for an equivalent number of Pre-Funded Warrants with an exercise price of $0.001. In addition, in certain circumstances, upon a fundamental transaction (as described in the Warrants), a holder of Warrants will be entitled to receive, upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Warrants immediately prior to such fundamental transaction or number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation. In lieu of receiving such Common Stock in the fundamental transaction, the Warrant holder may elect to have the Company or the successor entity purchase the holder’s Warrant for its fair market value measured by the Black-Scholes method.


The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

The foregoing descriptions of the terms of the Underwriting Agreement, Series A Warrants and Series B Warrants are each qualified in their entirety by reference to the Underwriting Agreement, form of Pre-Funded Warrant, the form of Series A Warrant and the form of Series B Warrant, respectively, which are attached as Exhibit 1.1, Exhibit 4.1, Exhibit 4.2 and Exhibit 4.3 hereto, respectively, and incorporated by reference herein.

A copy of the legal opinion of Cooley LLP relating to the validity of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto.

 

Item 8.01

Other Events

On July 2, 2025 and July 3, 2025, the Company issued press releases announcing the launch and pricing of the Offering, respectively, copies of which are filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Exhibit Description
 1.1    Underwriting Agreement, dated July 2, 2025, by and between Inovio Pharmaceuticals, Inc. and Piper Sandler & Co.
 4.1    Form of Pre-Funded Warrant.
 4.2    Form of Series A Warrant.
 4.3    Form of Series B Warrant.
 5.1    Opinion of Cooley LLP.
23.1    Consent of Cooley LLP (included in Exhibit 5.1).
99.1    Press Release.
99.2    Press Release.
104    Cover Page Interactive Data File (formatted as inline XBRL).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      INOVIO PHARMACEUTICALS, INC.
Date: July 7, 2025      

/s/ Peter Kies

      Peter Kies
      Chief Financial Officer

FAQ

How many HSBC (HSBC) shares were repurchased on 4 July 2025?

A total of 601,094 ordinary shares were bought—267,494 in the UK and 333,600 in Hong Kong.

What is the cumulative size of HSBC’s 2025 share-buyback so far?

Since 6 May 2025, HSBC has repurchased 199,313,865 shares for about US$2.33 billion.

At what average price did HSBC buy back shares in the UK on 4 July 2025?

The volume-weighted average price was £8.8395 per share.

What is HSBC’s current share count after the latest cancellations?

Outstanding ordinary share capital stands at 17,456,148,272 shares with full voting rights.

Does HSBC hold any treasury shares after this transaction?

No; the company reports zero ordinary shares held in treasury.

Where can investors find the detailed trade list for the buyback?

Morgan Stanley’s individual trades are provided in the RNS PDF at http://www.rns-pdf.londonstockexchange.com/rns/8840P_1-2025-7-4.pdf.
Inovio Pharmaceu

NASDAQ:INO

INO Rankings

INO Latest News

INO Latest SEC Filings

INO Stock Data

74.82M
50.67M
0.68%
36.6%
15.3%
Biotechnology
Pharmaceutical Preparations
Link
United States
PLYMOUTH MEETING